Formulation and specifications: Tablets: 2.5mg, 5mg, 10mg
Indications:
1. Advanced renal cell carcinoma (RCC) that has failed prior treatment with sunitinib or sorafenib, with data based primarily on clear cell renal carcinoma.
2. Combination with lenvatinib for advanced RCC that has failed or progressed on prior antiangiogenic therapy.
Key points for rational drug use:
1. Hepatic impairment increases everolimus exposure, and dosing is adjusted as follows: (1) Mild hepatic impairment (Child-Pugh class A): the recommended dose is 7.5 mg per day; if not well tolerated, the dose may be reduced to 5 mg per day.(2) Moderate hepatic impairment (Child-Pugh class B): the recommended dose is 5 mg per day; if (3) Severe hepatic impairment (Child-Pugh Class C): If the expected benefit is higher than the risk, 2.5 mg per day may be used, but this dose should not be exceeded.
2. Attention must be paid to common stomatitis, etc. during drug administration; special attention should be paid to the occurrence of non-infectious pneumonia.
3. Avoid the combined use of potent CYP3A4 inducers.
4. Live vaccination should be avoided during the treatment of this product, and close contact with people who have received live vaccines should be avoided.
For additional precautions for combination therapy with lenvatinib, please refer to the “Lenvatinib” section.